Investigational drug · Phase 3
ONO-2808
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy (MSA).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "ONO-2808"
First trial start
2023
Sep 22, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ONO-2808", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple System Atrophy, Parkinson Variant
- Multiple System Atrophy (MSA)
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "ONO-2808" as an intervention, largest first.
- A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)Pivotal-lookingNot yet recruiting
Ono Pharmaceutical Co., Ltd.Industry
NCT07825402 · 486 participants (planned) · Start Jan 2027 · Primary completion Oct 2029
Drug: ONO-2808 · For: Multiple System Atrophy, Parkinson Variant
Ono Pharmaceutical Co., Ltd.Industry
NCT04578028 · 94 participants · Start Aug 19, 2020 · Primary completion Aug 26, 2021
Drug: ONO-2808; Placebo · For: Neurodegenerative Diseases
Sites: London, United Kingdom
- A Phase 2 Study of ONO-2808 in Patients With Multiple System AtrophyActive, not recruiting
Ono Pharmaceutical Co., Ltd.Industry
NCT05923866 · 92 participants · Start Sep 22, 2023 · Primary completion Sep 15, 2025
Drug: ONO-2808; Placebo · For: Multiple System Atrophy (MSA)
Sites: Fountain Valley, California; Los Angeles, California; Palo Alto, California · 35 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.